| Autor: |
Gustavo Guimarães Moreira Balbi, Marcelo de Souza Pacheco, Odirlei Andre Monticielo, Andreas Funke, Adriana Danowski, Mittermayer Barreto Santiago, Henrique Luiz Staub, Jozelia Rêgo, Danieli Castro Oliveira de Andrade |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Advances in Rheumatology, Vol 60, Iss 1, Pp 1-14 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2523-3106 |
| DOI: |
10.1186/s42358-020-00125-9 |
| Popis: |
Abstract Background The term Direct Oral Anticoagulants (DOACs) refers to a group of drugs that inhibit factor Xa or thrombin. Even though their use for treating different thrombotic or prothrombotic conditions is increasing recently, there is no compelling evidence indicating that those medications are safe in all antiphospholipid syndrome (APS) patients. Methodology To address this issue, specialists from the Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology performed a comprehensive review of the literature regarding DOACs use in APS to answer the three following questions: (1) potential mechanisms of action of these drugs that could be relevant to APS pathogenesis, (2) DOACs interference on lupus anticoagulant testing, and (3) the efficacy of DOACs in APS. Position statement After critically reviewing the relevant evidence, the authors formulated 8 Position Statements about DOACs use in APS. Conclusion DOACs should not be routinely used in APS patients, especially in those with a high-risk profile (triple positivity to aPL, arterial thrombosis, and recurrent thrombotic events). In addition, DOACs interferes with LA testing, leading to false-positive results in patients investigating APS. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink